513 related articles for article (PubMed ID: 23084013)
1. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG retention index and biologic prognostic parameters in breast cancer.
García Vicente AM; Castrejón ÁS; Relea Calatayud F; Muñoz AP; León Martín AA; López-Muñiz IC; Del Mar Muñoz Sánchez M; Cordero García JM; Becerra Nakayo EM
Clin Nucl Med; 2012 May; 37(5):460-6. PubMed ID: 22475895
[TBL] [Abstract][Full Text] [Related]
3. Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors.
García Vicente AM; Soriano Castrejón A; Cruz Mora MA; González Ageitos A; Muñoz Sánchez Mdel M; León Martín A; Espinosa Aunión R; Relea Calatayud F; Muñoz Madero V; Chacón López-Muñiz I; Cordero García JM; Jiménez Londoño GA
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):72-9. PubMed ID: 23053321
[TBL] [Abstract][Full Text] [Related]
4. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Shigekawa T; Fukatsu K; Kondo N; Yamamoto M; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
Jpn J Clin Oncol; 2008 Apr; 38(4):250-8. PubMed ID: 18407934
[TBL] [Abstract][Full Text] [Related]
6. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.
Buck A; Schirrmeister H; Kühn T; Shen C; Kalker T; Kotzerke J; Dankerl A; Glatting G; Reske S; Mattfeldt T
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1317-23. PubMed ID: 12271413
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
9. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
[TBL] [Abstract][Full Text] [Related]
10. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
[TBL] [Abstract][Full Text] [Related]
11. Reliability of
Jena A; Taneja S; Singh A; Negi P; Sarin R; Das PK; Singhal M
AJR Am J Roentgenol; 2017 Sep; 209(3):662-670. PubMed ID: 28678576
[TBL] [Abstract][Full Text] [Related]
12. Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid.
Leboeuf R; Bénard F; Langlois MF
Clin Nucl Med; 2006 Jul; 31(7):382-5. PubMed ID: 16785803
[TBL] [Abstract][Full Text] [Related]
13. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes of breast cancer: metabolic correlation with ¹⁸F-FDG PET/CT.
García Vicente AM; Soriano Castrejón Á; León Martín A; Chacón López-Muñiz I; Muñoz Madero V; Muñoz Sánchez Mdel M; Palomar Muñoz A; Espinosa Aunión R; González Ageitos A
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1304-11. PubMed ID: 23632960
[TBL] [Abstract][Full Text] [Related]
15. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma.
Ekmekcioglu O; Aliyev A; Yilmaz S; Arslan E; Kaya R; Kocael P; Erkan ME; Halac M; Sonmezoglu K
Nucl Med Commun; 2013 Nov; 34(11):1055-67. PubMed ID: 24025919
[TBL] [Abstract][Full Text] [Related]
16. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
[TBL] [Abstract][Full Text] [Related]
17. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
19. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
[TBL] [Abstract][Full Text] [Related]
20. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
Hatt M; Groheux D; Martineau A; Espié M; Hindié E; Giacchetti S; de Roquancourt A; Visvikis D; Cheze-Le Rest C
J Nucl Med; 2013 Mar; 54(3):341-9. PubMed ID: 23327900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
